STAT11h
Alnylam drug wins FDA approval for progressive heart disease
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Tivic Health targets FDA approval for Entolimod within 18 months, highlights transformation into biopharma
Ernst emphasized the strategic transformation of Tivic into a diversified therapeutics company, combining biologic and bioelectronic approaches to address immune dysregulation. This includes ...
Cancer Therapy Advisor22h
FDA Grants Traditional Approval to Keytruda for HER2+ Gastric/GEJ Cancer
The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.
Healio11h
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
STAT9h
Alnylam enters the ATTR-CM drug race
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
Pharmaceutical Technology on MSN16h
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
"FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease" was originally created and published by Pharmaceutical ...
Pharmaceutical Technology on MSN8h
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug
Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.